)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Transgene
Transgene (TNG) investor relations material
Transgene Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary9 Nov, 2026
Executive summary
TG4050 sustained 100% disease-free survival (DFS) after more than 3 years of follow-up in early-stage head and neck cancer; Phase 2 remains ongoing.
TG4070 entered Phase 1 clinical development in resected non-small cell lung cancer (NSCLC), with five French sites open and recruiting.
Cash and current financial assets of €84.3 million at September 30, 2026, support financial visibility through early 2028 under current plans.
Financial highlights
9M 2026 operating income was €4.3 million versus €6.1 million in 9M 2025; research tax credit contributed €3.9 million versus €5.8 million.
Cash, cash equivalents and other current financial assets totaled €84.3 million at September 30, 2026, versus €111.9 million at December 31, 2025.
Outlook and guidance
TG4050 Phase 2 immunological data expected by year end 2026, with presentation targeted for a 2027 scientific conference; topline results expected by end-Q1 2028.
Phase 3-ready TG4050 manufacturing capacity targeted by end-2027; scalable cell line-based manufacturing is in preparation.
Current plans indicate sufficient cash for financial visibility until early 2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Transgene
- TG4050 achieved 100% 3-year DFS in HNSCC Phase 1; net loss narrowed, cash reserves strong.TNG
H1 2026 - Individualized neoantigen vaccines show strong efficacy and scalability for early-stage cancers.TNGInvestor presentation
- Lead neoantigen vaccine TG4050 achieved 100% 2-year DFS in HNSCC, supporting platform growth.TNGInvestor presentation
- TG4050 shows 100% 2-year DFS in Phase 1; TG4070 launches Phase 1 in NSCLC with scalable AI-driven tech.TNGStatus update
- TG4050 Phase 2 enrollment complete; topline data due Q1 2028; strong cash position maintained.TNGQ1 2026
- TG4050 achieved 100% 2-year DFS in Phase 1 HNSCC; funding secured to early 2028.TNGH2 2025
- TG4050 achieved 100% 2-year DFS in Phase I, with strong funding and new leadership in place.TNGH1 2025
- Strong clinical progress and financial runway secured through Q4 2025 after debt conversion.TNGH1 2024
- TG4050 achieved 100% relapse-free survival at 30 months, with phase II ongoing.TNGStatus Update
Transgene
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Transgene SA is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company's core expertise lies in the design and development of therapeutic vaccines and oncolytic viruses. Transgene leverages advanced viral vector technology to create targeted treatments that aim to induce immune responses against cancer cells, either by directly attacking them or by enhancing the body's immune system to do so. Key products in its clinical-stage pipeline include TG4050, an individualized therapeutic vaccine developed using the myvac platform, and TG4001, aimed at treating HPV-positive cancers. The company also develops oncolytic viruses like BT-001 and TG6050 under its Invir.IO platform. The company is headquartered in Illkirch-Graffenstaden, France, and its shares are listed on the Euronext Paris.